Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

NCT00620854 is registered in ClinicalTrials.gov with Tarsa Therapeutics, Inc. as lead sponsor.

NCT NCT00620854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00620854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
Lead sponsor
Tarsa Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
April 30, 2008
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis